# NewAmsterdam Pharma Co N.V. (NAMS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/newamsterdam-pharma-co-n-v/ JSON: https://steadybase.io/company/newamsterdam-pharma-co-n-v.json Checked Nov 21, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: NewAmsterdam Pharma Co N.V.
- Ticker: NAMS, NAMSW (Nasdaq, Nasdaq)
- SEC CIK: 0001936258
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Narrden, P7
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: newamsterdampharma.com
- LinkedIn: https://www.linkedin.com/company/new-amsterdam-pharma-corporation
- Next earnings date: Jan 8, 2027

## Key facts

- Revenue: $22.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.html
- Operating income: -$225.7M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.html
- Net income: -$203.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.html
- SG&A: $106.4M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 18, 2026). Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/0001193125-26-056029-index.html
- Employees: 100 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Shares outstanding: 119,929,998 as of Nov 2, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526446228/0001193125-26-446228-index.html
- Auditor: Deloitte Accountants B.V, Eindhoven, The Netherlands, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm

## Business

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $22.5M | -$225.7M | -$203.8M | $106.4M |
| Dec 31, 2024 | $45.6M | -$176.3M | -$241.6M | $70.4M |
| Dec 31, 2023 | $14.1M | -$183.0M | -$176.9M | $37.6M |
| Dec 31, 2022 | $102.7M | -$3.6M | -$22.6M | $19.5M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/newamsterdam-pharma-co-n-v.json

## Officers and directors

- Michael H. Davidson, Chief Executive Officer. Source: Form 4 filed Sep 15, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526391985/0001193125-26-391985-index.htm
- Ian Somaiya, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/m-ian-somaiya-0990812. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Mayur Ian Somaiya, Chief Financial Officer. Source: Form 4 filed Jan 22, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526019686/0001193125-26-019686-index.htm
- Robert William Gunning, Vice President, Controller. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526381953/0001193125-26-381953-index.htm
- Johannes Jacob Pieter Kastelein, Chief Scientific Officer. Source: Form 4 filed Aug 25, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526365202/0001193125-26-365202-index.htm
- Robert W. Gunning, principal accounting officer. Source: 8-K filed Aug 14, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm
- Louise Frederika Kooij, Chief Accounting Officer. Source: Form 4 filed Jul 22, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526312387/0001193125-26-312387-index.htm
- John Kastelein, M.D., Chief Scientific Officer, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Louise Kooij, Chief Accounting Officer. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Mark C. McKenna, Vice Chair, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- William H. Lewis, J.D., M.B.A., Chair, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Adele Gulfo, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- James N. Topper, M.D., Ph.D., Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Janneke van der Kamp, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- John W. Smither, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Louis Lange, M.D., Ph.D., Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- Wouter Joustra, Non-Executive Director. Source: 10-K filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm

## Recent 8-K events

- Nov 4, 2026: Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526446219/nams-20261104.htm
- Sep 29, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526406063/nams-20260929.htm
- Sep 21, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526396716/nams-20260921.htm
- Aug 14, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526333827/nams-20260805.htm
- Jul 24, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526315163/nams-20260724.htm
- Jul 22, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm
- Jun 3, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526254615/nams-20260602.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526210283/nams-20260507.htm
- Apr 24, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/nams-20260420.htm

## Insider trades (Form 4)

- Sep 30, 2026: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 50,246 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526412431/0001193125-26-412431-index.htm
- Sep 14, 2026: Michael H. Davidson (Chief Executive Officer) bought 10,000 shares, about $226,500. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526391985/0001193125-26-391985-index.htm
- Sep 4, 2026: John W. Smither (Director) sold 1,600 shares, about $40,512. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526386508/0001193125-26-386508-index.htm
- Aug 24, 2026: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 125,000 shares, about $3.4M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526365202/0001193125-26-365202-index.htm
- Jul 20, 2026: Louise Frederika Kooij (Chief Accounting Officer) sold 105,000 shares, about $3.2M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526312387/0001193125-26-312387-index.htm
- Jun 22, 2026: Louise Frederika Kooij (Chief Accounting Officer) sold 40,000 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526281062/0001193125-26-281062-index.htm
- May 26, 2026: Louise Frederika Kooij (Chief Accounting Officer) sold 65,000 shares, about $2.3M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526241983/0001193125-26-241983-index.htm
- Mar 11, 2026: Louis G. Lange (Director) sold 44,619 shares, about $1.4M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526104239/0001193125-26-104239-index.htm
- Mar 9, 2026: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 300,000 shares, about $9.1M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526099073/0001193125-26-099073-index.htm
- Mar 6, 2026: Louis G. Lange (Director) sold 28,186 shares, about $828,950. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/0001193125-26-100798-index.htm
- Mar 2, 2026: Michael H. Davidson (Chief Executive Officer) sold 443,707 shares, about $14.8M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526085947/0001193125-26-085947-index.htm
- Feb 26, 2026: Michael H. Davidson (Chief Executive Officer) sold 306,293 shares, about $10.6M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526078718/0001193125-26-078718-index.htm
- Feb 20, 2026: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 45,481 shares, about $1.6M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526067260/0001193125-26-067260-index.htm
- Jan 28, 2026: Louise Frederika Kooij (Chief Accounting Officer) sold 72,428 shares, about $2.3M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526029526/0001193125-26-029526-index.htm
- Jan 26, 2026: Louise Frederika Kooij (Chief Accounting Officer) sold 72,572 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526025012/0001193125-26-025012-index.htm

## Latest filings

- 8-K filed Sep 29, 2026: https://www.sec.gov/Archives/edgar/data/1936258/000119312526406063/nams-20260929.htm
- 10-K filed Feb 18, 2026: https://www.sec.gov/Archives/edgar/data/1936258/000119312526056029/nams-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1936258/000119312526333824/nams-20260630.htm
- 20f filed Mar 31, 2023: https://www.sec.gov/Archives/edgar/data/1936258/000095017023011412/nams-20221231.htm
- DEF 14A filed May 6, 2026: https://www.sec.gov/Archives/edgar/data/1936258/000119312526207562/nams-20260506.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

